Pfizer, Biohaven

Pfizer settles Biohaven kickback claims case for $59.7m
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.
Pfizer shells out nearly $60M to resolve Nurtec kickback claims inherited in Biohaven buyout
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments intended to boost prescriptions. | Pfizer—which purchased Biohaven for $11.6 billion in 2022—is committing more than $59.
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer pays close to $60 million to resolve kickback allegations
Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec.
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.
Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer offers $60m to settle prescriber kickback claims
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine drug Nurtec ODT.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT,
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal healthcare programs.
Pfizer Settles $59.7M Medicare Kickback Case Over Biohaven Practices
Pfizer (NYSE:PFE) has agreed to pay $59.7 million to resolve allegations that Biohaven Pharmaceuticals, acquired by Pfizer in October 2022, defrauded Medicare and other healthcare programs by offering kickbacks to
policymed.com3d
Pfizer’s Subsidiary Biohaven Settles for Nearly $60M Over Speaker Programs: Complaint included Significant Open Payments Under Reporting
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
Cantor Fitzgerald sees upside in select biotech stocks
In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, ...
STAT2d
U.S. health agencies see some chaos — but an FDA approval gets through
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
EurekAlert!2d
Mizzou researchers invent a new tool to help lower the cost of tomorrow’s medicine
University of Missouri researchers and collaborators have developed a new chemical tool that could help lower the cost of ...
Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Average Price Target from Analysts
Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports.